GuidelineMMWR. Morbidity and mortality weekly report2025
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025.
Guideline in MMWR. Morbidity and mortality weekly report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.Human vaccines & immunotherapeutics · 2026Pooled it
- Comparative efficacy of nutritional supplements for the prevention of respiratory tract infections in children: a systematic review and network meta-analysis.BMC infectious diseases · 2026Pooled it
- Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.Pediatrics · 2026Trial
- Expenditures attributable to infant lower respiratory tract infection due to respiratory syncytial virus in the US: A real-world study using the PharMetrics Plus Database, 2015-2023.Human vaccines & immunotherapeutics · 2026Article
- Regional inequality in infant RSV morbidity and mortality burden in the era of expanded RSV passive immunisation: a global projection modelling study.EClinicalMedicine · 2026Article
- Article
- Decreasing the Burden of West Nile Virus Disease: The Need for More Prevention Measures.The American journal of tropical medicine and hygiene · 2026Article
- Respiratory Syncytial Virus-Associated Disease in Children Receiving Intensive Care.JAMA network open · 2026Article
- Report from the inaugural 2025 Asia-UK Maternal-Neonatal Infection and Immunity Network (AMMuNet) symposium.NPJ vaccines · 2026Article
- CAUSAL-RSV: A study protocol for a causal mediation analysis of RSV vaccine effects in infants using real-world data.medRxiv : the preprint server for health sciences · 2026Article
- Outcomes of Severe Acute Respiratory Diseases Caused by SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus.Microorganisms · 2026Article
- Correlations and Timeliness of Respiratory Syncytial Virus Surveillance Indicators-United States, 2018-2024.Influenza and other respiratory viruses · 2026Article
- Respiratory Syncytial Virus Immunization Intention During Pregnancy and Infancy.JAMA network open · 2026Article
- Evaluating Analytic Approaches to Determining Respiratory Syncytial Virus Seasonality-United States, 2014-2024.Influenza and other respiratory viruses · 2026Article
- RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein.Vaccines · 2026Review
- Genomic surveillance of a deeply sampled local population reveals age-specific drivers of RSV transmission.medRxiv : the preprint server for health sciences · 2026Article
- Factors Affecting Maternal Respiratory Syncytial Virus Vaccination and the Impact on Infant Hospitalization During the 2023-2024 Season in Dallas, Texas.Public health reports (Washington, D.C. : 1974) · 2026Article
- Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States.Vaccines · 2026Article
- RSV Prevention Products and Severe RSV-Associated Disease Among Infants.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Before the introduction of universal respiratory syncytial virus (RSV) immunization recommendations for infants, RSV was the leading cause of hospitalization among infants in the United States. Since 2023, CDC's Advisory Committee on Immunization Practices (ACIP) has recommended that all infants be protected against RSV-associated lower respiratory tract infection (LRTI) through either 1) maternal RSV vaccination during pregnancy (Abrysvo, Pfizer) or 2) administration of nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting RSV monoclonal antibody, to the infant. In June 2025, the Food and Drug Administration licensed clesrovimab (Enflonsia, Merck), a second long-acting RSV monoclonal antibody, for prevention of RSV-associated LRTI in infants. Since September 2024, the ACIP Maternal/Pediatric RSV Work Group has reviewed evidence regarding the safety and efficacy of clesrovimab use in infants. On June 26, 2025, ACIP recommended clesrovimab as a second long-acting monoclonal antibody product that could be used as an alternative to nirsevimab for prevention of RSV-associated LRTI among infants aged <8 months who are born during or entering their first RSV season and who are not protected through maternal RSV vaccination. All infants should be protected against RSV-associated LRTI through use of one of these three products (i.e., maternal RSV vaccination or administration of nirsevimab or clesrovimab to the infant). No one product is preferred; the choice should be guided by parent preference, product availability, and timing of the infant's birth relative to the RSV season.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.